ACAD

Equibles Rating blended score · not investment advice

Overall

Buy

Technical · trend & momentum Buy

◦ 50 / 200-day cross no cross

+ Price vs 200-day avg +12% above

+ Price vs 50-day avg +17% above

− RSI (14) 78 · overbought

+ MACD trend positive

◦ 52-week position 73% · mid-range

Sentiment · smart money Neutral

◦ Trend (MA cross) 50d $22 › 200d $23 — 200d above 50d

+ Institutional flow 4 of 343 funds reported for Jun 30 · net +332 sh shares · +1 new

− Insider flow Net -$219.8K over 90 days · 100% sells

− Short interest 6.90% of float · ▲ +0.5% MoM · 11.3 days cover

◦ Volume signal Volume near normal

+ Institution breadth 343 holders — near 3-yr high, broad support

Fundamentals Excellent

+ Revenue growth +40% Y/Y

+ Gross margin 94%, contracting

+ EPS growth +69% Y/Y

+ Free cash flow $105.1M

◦ Valuation P/E 11.8 · in line

+ Balance sheet net cash $177.7M

Blended from price, positioning & fundamentals · daily-close · not investment advice.

Up next

Next earnings call

Aug 5, 2026 Est · unconfirmed · in 4 wks

FQ3-26 quarter ends

~Sep 30, 2026 Est

Latest filing: 10-Q

filed May 7, 2026

AI Brief

TL;DR.

Bullish

Bearish

AI-generated from the earnings call and 8-K · may contain errors · not investment advice

Technicals

trend & momentum for long-term holders Buy

1 · 2 · 3

50 / 200-day cross

no cross Neutral

Price vs 200-day avg

+12% above Bullish

Price vs 50-day avg

+17% above Bullish

RSI (14)

78 · overbought Bearish

MACD trend

positive Bullish

52-week position

73% · mid-range Neutral

Market signals — smart money & positioning

Mixed

Trend (MA cross) No cross

50d $22 › 200d $23 — 200d above 50d

Institutional flow Accumulating

4 of 343 funds reported for Jun 30 · net +332 sh shares · +1 new

Insider flow Distributing

Net -$219.8K over 90 days · 100% sells

Short interest Rising

6.90% of float · ▲ +0.5% MoM · 11.3 days cover

Volume signal Normal

Volume near normal

Institution breadth Multi-yr high

343 holders — near 3-yr high, broad support

Price context

position in its 52-week range

52-wk low $20 Now $26 · 73% 52-wk high $28

vs 200-day avg +12% vs 50-day avg +17%

Illustrative technical + ownership context — a signal mix, not investment advice.

Key metrics

the company's own KPIs, from its earnings releases, calls, and filings

Metric	Latest	Period	YoY
Net product sales of DAYBUE	$101M	Q1 2026	—
Net product sales of NUPLAZID	$167M	Q1 2026	—
DAYBUE sales	$101M	Q1 2026 call	—
non-GAAP NUPLAZID sales non-GAAP	$167M	Q1 2026 call	—
NUPLAZID demand growth	8%	Q1 2026 call	—
NUPLAZID volume growth	9%	FY25	—

Figures exactly as the company stated them · click a metric with a to chart its history · period links open the stating document · "call" marks figures stated on the earnings call, "filing" figures stated in the 10-K/10-Q · YoY needs the prior-year figure on file

Versus peers

Biotechnology — same industry group

Open screener →

Company	Mkt cap	YTD	Rev growth Y/Y	P/E	Short % shares
ACAD Acadia Pharmaceuticals Inc this stock	$4.45B	-2.8%	+40.4%	11.8	6.9%
AKTX Akari Therapeutics Plc	$998.08B	-5.7%	—	—	0.0%
ONC BeOne Medicines Ltd.	$488.96B	+1.9%	+22179.2%	995.1	0.1%
VRTX Vertex Pharmaceuticals Inc / Ma	$134.41B	+16.8%	+46.2%	31.4	1.8%
REGN Regeneron Pharmaceuticals, Inc.	$69.33B	-15.7%	+20.8%	16.1	3.2%

Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding

At a glance

key data from every section

Ownership

Institutional Holders Accumulating

Holders

344

% held: 91.7%
Reported: 4 of 343
Top holder: BAKER BROS. ADVISORS LP

Held Float

View

Held by Funds

Fund positions

320

View

Short & Settlement

Short Interest Rising

Shares short

11.8M

Days to cover: 11.3d
Change: +58.7K sh

View

Short Volume

Short vol %

44%

As of: Jul 6, 2026

Short Total

View

Fails to Deliver

FTD shares

25.1K

Value: $540.7K
As of: Jun 8, 2026

View

Off-Exchange

Off-exchange %

37.4%

Week of: May 4, 2026

Off-exch Lit

View

Smart Money

Insider Trades Net selling

Net (90d)

-$219.8K

Buyers / Sellers: 0 / 2

Buyers Sellers

View

Congressional Trades Sell

Member

Christopher L. Jacobs

Amount: $1.0K–$15.0K
Traded: Jun 16, 2022

View

Financials

Revenue (FY)

$1.1B

Net income (FY): $391.0M
EPS diluted: $2.30

View

Filings

SEC Filings

Latest

8-K

Filed: May 29, 2026
This year: 9

View

Proposed Sales

Value

$297.0K

Shares: 11.4K
Filed: Jun 26, 2026

View

Earnings & Events

Earnings Calls

Last call

May 19, 2026

View

Investor Relations

Performance

	5D	20D	120D	MTD	YTD
ACAD	+9.5%	+21.2%	-3.5%	+2.7%	-2.8%
SPY	+1.4%	-1.3%	+8.0%	-0.3%	+9.2%
vs SPY	+8.1%	+22.4%	-11.5%	+2.9%	-12.0%

Price & Indicators

Technicals

Key metrics

Versus peers

At a glance

Performance